Company intelligence / Profile preview
Endo International plc
Malvern, Pennsylvania, United Statesendo.com ↗
- Ownership
- Public · NDOI
- Employees
- ~492
- Development stage
- Commercial
01
Overview
Endo has multiple approved products including Xiaflex (collagenase clostridium histolyticum) for Dupuytren's contracture and Peyronie's disease, which generated $475 million in sales in 2023. The company recently emerged from bankruptcy in 2024 with a reorganized structure and reduced debt.
- Therapeutic areas
- RheumatologyImmunologyNeurologyMen's Health
- Modalities
- Small moleculesenzymesmolecular gluemonoclonal antibody
- Industry
- Biotech
02
Drug pipeline
29 assets28 more assets in the full pipeline.
03
Partnerships
Mallinckrodt Pharmaceuticals (merger announced March 2025)
Beyond the preview
Go deeper on Endo International plc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endo International plc.